Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

By A. Fournier, F. Berrino, Francoise Clavel-Chapelon. Breast Cancer Research and Treatment, 2007

688 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. (2015, background): “However, observational data suggest that progesterone or dydrogesterone (5, 89) may be associated with a lower risk, but further studies are required to confirm this.”
The 2022 hormone therapy position statement of The North American Menopause Society (2022, neutral): “Role of type of hormone use, dose, and route of administration Some but not all observational data suggest that MP and dydrogesterone may have a lesser association with breast cancer, whereas other synthetic progestogens such as MPA may have a more adverse effect.(268) Randomized trials are needed t”
Epidemiological characteristics of and risk factors for breast cancer in the world (2019, result): “They reported that this risk is lower in estrogen–progesterone or estrogen–dydrogesterone methods than other methods.(74) The result of a case–control study showed that the use of HRT in postmenopausal women and in carriers of BRCA1 mutations does not increase the risk of developing breast cancer.”